Disc Medicine (IRON) Expected to Announce Quarterly Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is projected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, analysts expect Disc Medicine to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Disc Medicine Stock Performance

IRON stock opened at $52.83 on Wednesday. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -13.27 and a beta of 0.73. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $68.86. The stock has a fifty day moving average of $55.77 and a 200-day moving average of $56.04.

Analyst Upgrades and Downgrades

IRON has been the subject of several research reports. TD Cowen initiated coverage on Disc Medicine in a research note on Thursday, February 27th. They set a “buy” rating for the company. Wedbush reiterated an “outperform” rating and set a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Scotiabank increased their price target on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 3rd. HC Wainwright reissued a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Stifel Nicolaus increased their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Disc Medicine currently has a consensus rating of “Buy” and a consensus target price of $93.80.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 1,610 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the sale, the chief operating officer now owns 40,555 shares of the company’s stock, valued at $2,213,491.90. This trade represents a 3.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total value of $470,625.00. Following the transaction, the insider now directly owns 14,035 shares in the company, valued at approximately $880,696.25. This represents a 34.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 346,617 shares of company stock valued at $19,182,953 in the last 90 days. Corporate insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.